This study is to evaluated the interruption schedule of NOAC in patients who undergo atrial fibrillation ablation. The investigators will compare the bleeding complications were classified as major and minor bleeding, thromboembolic, vascular complications, Re-admission and increased in the length of hospital stay during the 30-day post-radiofrequency catheter ablation(RFCA) period among patients who interrupt NOAc 24hours before ablation and patients who stop NOAC in the morning of the procedure.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
433
novel oral anticoagulant includes 'dabigatran,Pradaxa®', 'rivaroxaban,Xarelto®', and 'apixaban, Eliquis®'.
novel oral anticoagulant includes 'dabigatran,Pradaxa®', 'rivaroxaban,Xarelto®', and 'apixaban, Eliquis®'.
Severance Cardiovascular Hospital, Yonsei University Health System
Seoul, South Korea
RECRUITINGincidence of major bleeding complications
Bleeding complication is assessed by physical examination or laboratory measurement
Time frame: during 30 days post-AF ablation.
incidence of thromboembolism
thromboembolism is diagnosed by both clinical situations and image studies combined.
Time frame: during 30 days post-AF ablation.
incidence of minor bleeding
Time frame: during 30 days post-AF ablation.
Re-admission rate related procedure
Time frame: during 30 days post-AF ablation.
length of hospital stay
Time frame: during 30 days post-AF ablation.
incidence of vascular complications
vascular complication is diagnosed by both clinical situations and image studies combined.
Time frame: during 30 days post-AF ablation.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.